Category News

Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment

Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment Emulate, Inc., the leading provider of next-generation in vitro models, today announced the publication “Integrating Liver-Chip Data into Pharmaceutical Decision-Making Processes” in Expert Opinion…

Read MoreEmulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment

Merck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy Merck (NYSE: MRK), known as MSD outside of the United States…

Read MoreMerck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Global Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com

Global Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com The “Cell Freezing Media Market Size, Share & Trends Analysis Report By Product (DMSO, Glycerol), By Application (Stem Cell…

Read MoreGlobal Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com

AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months

AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months –AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a Lentiviral vector (LVV) expansion to its AGCellerate program designed to deliver…

Read MoreAGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity Ahead of discussions at the United Nations General Assembly (UNGA78), IFPMA, the association representing the research-based pharmaceutical industry, warned that…

Read MoreAhead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity

Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone…

Read MoreStudy Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry IRLCA und EAD haben die Grundlage für eine bahnbrechende Zusammenarbeit gelegt, die regulatorische Compliance und Technik vereint, um beispiellose Effizienz und Exzellenz während des…

Read MoreIRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry

European Commission Expands Merck’s ERVEBO®Indication to Include Children 1 Year of Age and Older

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older Merck known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved…

Read MoreEuropean Commission Expands Merck’s ERVEBO®Indication to Include Children 1 Year of Age and Older

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees will celebrate a…

Read MoreBristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research

Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA Plus LENVIMA® in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Merck (NYSE: MRK), known as MSD outside of the United States…

Read MoreMerck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years Novartis today announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data demonstrated that with…

Read MoreNovartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States

Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College, one of the nation’s oldest and largest historically Black academic health…

Read MoreGilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States